Avelumab
- Generic Name
- Avelumab
- Brand Names
- Bavencio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1537032-82-8
- Unique Ingredient Identifier
- KXG2PJ551I
- Background
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, respectively. It is used in the treatment of Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
- Indication
Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
It is also indicated as the maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma (UC), which has not progressed with first-line platinum-containing chemotherapy. In the US, avelumab is also indicated to treat locally advanced or metastatic UC with disease progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Avelumab is indicated, in combination with axitinib, for the first-line treatment of advanced renal cell carcinoma (RCC).
- Associated Conditions
- Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
- Associated Therapies
- First Line Chemotherapy, Maintenance therapy
K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor
- Conditions
- Interventions
- First Posted Date
- 2018-04-09
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 60
- Registration Number
- NCT03491345
- Locations
- π°π·
Division of Medical Oncology, Severance Breast Cancer Clinic, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Avelumab/Gemcitabine in Sarcomatoid RCC
- First Posted Date
- 2018-03-30
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 6
- Registration Number
- NCT03483883
- Locations
- πΊπΈ
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- PH Research, S.L.
- Target Recruit Count
- 7
- Registration Number
- NCT03481920
- Locations
- πͺπΈ
Hospital Universitario La Paz, Madrid, Spain
πͺπΈHospital Universitario Fuenlabrada, Fuenlabrada, Madrid, Spain
πͺπΈHospital Ramon y Cajal, Madrid, Spain
Phase I/II Study of Avelumab in Pediatric Cancer Participants
- First Posted Date
- 2018-03-02
- Last Posted Date
- 2024-06-24
- Target Recruit Count
- 21
- Registration Number
- NCT03451825
- Locations
- π¨π¦
The Hospital for Sick Children, Toronto, Canada
π°π·Seoul National University Hospital, Seoul, Korea, Republic of
π¨π¦Children's Hospital - London Health Sciences Centre, London, Canada
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT03440567
- Locations
- πΊπΈ
City of Hope Medical Center, Duarte, California, United States
Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 21
- Registration Number
- NCT03439501
- Locations
- π°π·
81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea, Seoul, Korea, Republic of
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Adrienne G. Waks
- Target Recruit Count
- 100
- Registration Number
- NCT03414658
- Locations
- πΊπΈ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
πΊπΈJohns Hopkins University, Baltimore, Maryland, United States
πΊπΈUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
Avelumab in Refractory Testicular Germ Cell Cancer.
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- National Cancer Institute, Slovakia
- Target Recruit Count
- 8
- Registration Number
- NCT03403777
- Locations
- πΈπ°
National Cancer Institute, Bratislava, Slovakia
Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT03399552
- Locations
- πΊπΈ
Memorial Sloan Kettering Commack, Commack, New York, United States
πΊπΈMemorial Sloan Kettering Westchester, Harrison, New York, United States
πΊπΈMemorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2019-08-21
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 7
- Registration Number
- NCT03395873
- Locations
- πΊπΈ
Penn State Cancer Institute, Hershey, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.